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To identify small molecules that selectively control
hematopoietic stem cell differentiation, we per-
formed an unbiased screen using primary human
CD34+ cells. We identified a plant-derived natural
product, euphohelioscopin A, capable of selectively
differentiating CD34+ cells down the granulocyte/
monocytic lineage. Euphohelioscopin A also inhibits
proliferation and induces differentiation of the mye-
loid leukemia cell lines THP-1 and HL-60. Mecha-
nistic studies revealed that euphohelioscopin A is
an activator of protein kinase C (PKC), and that the
promonocytic effects of this natural product are
mediated by PKC activation. In addition to shedding
insights into normal hematopoiesis, this work may
ultimately facilitate the application of stem cell thera-
pies to a host of myeloid dysfunctions.
INTRODUCTION
Among the best characterized adult stem cells are hematopoi-
etic stem cells (HSCs), which can self-renew and differentiate
into all blood lineages. At each step in this process, cells lose
some of the differentiation and proliferation potential of their
upstream progenitor. This phenomenon can be harnessed as
a strategy against blood malignancies and leukemias that arise
from the oncogenic transformation of a progenitor rather than
a fully differentiated cell. In those cases, forcing the malignant
progenitors to differentiate can put an end to their invasive prolif-
eration (Leszczyniecka et al., 2001; Nowak et al., 2009, Petrie
et al., 2009). In contrast, numerous conditions lead to the deple-
tion of specific blood lineages, either as a direct result of bone
marrow failure or as a consequence of leukemia, viral infection,
or even aggressive treatments including radiation and chemo-
therapy. The ability to generate sufficient quantities of differenti-
ated, functional cells to replenish the deficient compartment has
long been a focus of regenerative medicine. To identify pharma-
cological agents that selectively differentiate hematopoietic
progenitors toward a desired effector cell, we carried out an994 Chemistry & Biology 19, 994–1000, August 24, 2012 ª2012 Elsevunbiased cell-based screen with primary human CD34+ cells.
The plant natural product euphohelioscopin A was identified
that induces differentiation of HSCs and THP-1 and HL-60 cells
to the granulocyte monocyte (GM) lineage by activation of pro-
tein kinase C (PKC).
RESULTS
Discovery of an HSC-Differentiating Natural Product
To identify molecules that modulate the differentiation of HSCs,
a library of 704 pure microbial and plant natural products was
screened in vitro using primary human CD34+ cells isolated
from mobilized peripheral blood. Cells were seeded into 384-
well plates (2,500 cells per well) in medium optimized for their
self-renewal, yet permissive to myeloerythroid differentiation
(serum-free medium supplemented with thrombopoietin [TPO],
stem cell factor [SCF], flt3 ligand [Flt-3L], and interleukin-6
[IL-6]) (Boitano et al., 2010; Murray et al., 1999). Compounds
were added at a final concentration of 1 mM and the cells were
incubated for 7 days, at which point the cultures, consisting of
a mixture of CD34+ and differentiated cells, were analyzed by
flow cytometry. The number of cells of each lineage and the
number of remaining progenitors in the culture were determined
based on cell surface phenotype: CD34+ (HSCs and progeni-
tors), CD34 (lineage-committed cells) CD45ra+ (GM lineage),
and CD45ra (megakaryocyte/erythrocyte lineage). Using this
assay, we observed that euphohelioscopin A, a lathyrane diter-
pene natural product first isolated in 1983 (Shizuri et al., 1983)
(Figure 1; see also Figure S1 available online), strongly induced
the differentiation of CD34+ cells toward the GM lineage
(CD34/CD45ra+).
Euphohelioscopin A Induces Differentiation to the GM
Lineage
Euphohelioscopin A decreased the percentage of CD34+ cells
after 7 days from 29% in the vehicle-treated cultures (DMSO
0.04%) to less than 13%, while the total number of viable nucle-
ated cells (TNCs) doubled compared to vehicle-treated cultures
(Figures 2A and 2B). Concurrently, CD45ra+ cells increased from
about 50% of the vehicle-treated cultures to 79% of the total
population when treated with euphohelioscopin A, suggest-
ing that the compound promotes selective differentiation ofier Ltd All rights reserved
Figure 1. Structure of Euphohelioscopin A
See also Figure S1.
Figure 2. Euphohelioscopin A Induces the Differentiation of CD34+
and THP-1 Cells
(A)–(C) characterize the population of cells generated by primary human
mobilized peripheral blood-derived CD34+ cells cultivated for 7 days, with
vehicle (DMSO 0.04%), euphohelioscopin A (600 nM), or PMA (0.6 nM). (A)
CD34 and CD45ra expression, analyzed by flow cytometry. (B) Fold change in
TNC (red), number of CD34+ cells (dark green), and number of CD34/CD45ra+
cells (medium blue), relative to vehicle. (C) Colony forming potential of 80
CD34+ cells following 7 days of culture with vehicle or euphohelioscopin A:
GEMM, dark green; E, red; G, medium blue; GM, dark blue; M, light blue.
(D) THP-1 cells were seeded in a 96-well plate (5,000 cells per well) in
RPMI +10% FBS, and treated with vehicle (0.01% DMSO) or euphohe-
lioscopin A (1 mM). TNC (DMSO, light green; eupho.A, dark green) and
CD11b expression (DMSO, orange; eupho.A, red) were quantified by flow
cytometry after the indicated number of days in culture. Data are represented
as mean ± SD.
See also Figure S2.
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was further supported by the observation that CD34/CD45ra+
cells make up to 71% of the final cell population after treatment
with compound for 7 days. The change in phenotype and TNC
resulted in no net change in the number of CD34+ cells com-
pared to vehicle, while the number of CD34/CD45ra+ increased
4-fold. Finally, CD34+ cells treated with euphohelioscopin A for
7 days generated 10-fold more cells positive for CD11b, an in-
tegrin characteristic of monocytes and macrophages, than the
vehicle. Together these results suggest that euphohelioscopin
A selectively promotes terminal differentiation of hematopoietic
stem and progenitor cells toward the myeloid lineage.
A key characteristic of stem and progenitor cells is the ability to
form colonies when plated in semisolid media. The composition
of the colonies reflects the lineage potential of the expanded
cells. The different colonies include macrophage (M), erythroid
(E), mixed GM, and mixed GM, E, and megakaryocyte (GEMM)
and represent a stage of hematopoietic differentiation between
HSCs and more terminally differentiated cells. The number of
colonies obtained is linearly proportional to the colony-forming
cell content of the input cell suspension where colonies contain-
ing cells of two or more lineages (mixed colonies) arise from an
earlier progenitor than those containing cells of a single lineage.
To confirm the differentiating effect of euphohelioscopin A, we
examined the colony forming potential of CD34+ cells expanded
with vehicle or euphohelioscopin A (2.5 mM) for 7 days. Eupho-
helioscopin A-treated cells showed a 3-fold decrease in total
colony-forming unit (CFU) potential compared to control cultures
(Figure 2C), suggesting that the cells had differentiated and the
cultures had decreased numbers of progenitors. Interestingly,
GM colonies were the only colonies that did not experience
a significant decrease in numbers; all other colonies decreased
by more than 4-fold. These results are consistent with the differ-
entiated phenotype of the 7 day cultured cells and support the
hypothesis that euphohelioscopin A treatment of CD34+ cells
selectively leads to an increase in nonproliferating, lineage-
restricted myeloid cells by driving the differentiation of CD34+
progenitor cells rather than inducing lineage-restricted CD34/
CD45ra+ cells to proliferate.Chemistry & Biology 19, 994–1000, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 995
Figure 3. The Differentiating Activity of Euphohelioscopin A Is Mediated by PKC
(A) Human mobilized peripheral blood CD34+ cells were seeded in 96-well plates (5,000 cells per well) and treated with vehicle (DMSO) or euphohelioscopin A at
the indicated doses, with or without the PKC inhibitor Go¨6983 (500 nM). Cell number and CD45ra expression were measured by flow cytometry after 7 days of
culture.
(B) THP-1 cells were seeded in 96-well plates (5,000 cells per well) and treated with vehicle (DMSO) or euphohelioscopin A at the indicated doses, with or without
the PKC inhibitor Go¨6983 (500 nM). Cell number and CD11b expression weremeasured by flow cytometry after 4 days of culture. Data are represented asmean ±
SD. DMSO, medium gray; DMSO + Go¨6983, black; euphohelioscopin A, dark gray; euphohelioscopin A + Go¨6983, light gray.
See also Figure S3.
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differentiation of leukemic cells with myeloid potential, we tested
its activity on two myeloid leukemia cell lines, HL-60 and THP-1.
After 4 days of culture with euphohelioscopin A (1 mM), 50%
of THP-1 cells were CD11b+ compared to less than 5% of
vehicle-treated cells, and the total number of cells was 2.6-fold
lower than in the control, indicating that the inhibition of prolifer-
ationwas concurrent with differentiation tomaturemacrophages
(Figure 2D). A similar effect was observed with HL-60 cells: after
4 days of treatment, 26% of cells were CD11b+ (compared to
less than 5% of control cells), and the total cell number was
decreased 8-fold (Figure S2).
Euphohelioscopin A Is a PKC Activator
The only biological activity reported to date for euphoheliosco-
pin A is inhibition of the drug transporter P-glycoprotein, as
measured in a mitoxantrone efflux assay (Barile et al., 2008).
However, this compound was significantly less effective than996 Chemistry & Biology 19, 994–1000, August 24, 2012 ª2012 Elsevrelated diterpenes (IC50: 14 mM, with maximal inhibition at
100 mM), suggesting that this mechanism does not account
for the molecule’s differentiation potential. A known pathway
for selective macrophage differentiation is through the ac-
tivation of PKC (Blumberg, 1988). Indeed, when tested in our
cell culture assays, PKC inhibitors were able to modulate eu-
phohelioscopin A-induced differentiation: addition of the PKC
inhibitor Go¨6983 (500 nM; higher concentrations resulted in
significant cytotoxicity) shifted the EC50 of euphohelioscopin
A in the CD34+ differentiation assay (from 590 nM to 2 mM,
Figure 3A), in the THP-1 differentiation assay (from 200 to
850 nM, Figures 3B and S3A), and in the HL-60 differen-
tiation assay (from 1.7 to 14.5 mM, Figure S3B). Euphohe-
lioscopin A was also able to induce the phosphorylation of
known downstream targets of PKC including ERK1/2 and
MARCKS (Figure 4A). These results suggest that the promono-
cytic effects of euphohelioscopin A are mediated through PKC
activation.ier Ltd All rights reserved
Figure 4. Euphohelioscopin A Is a PKC Activator
(A) HEK293T cells were treated for 10 min with vehicle, euphohelioscopin A or
PMA at the indicated concentrations, and western blots were performed for
phosphorylation of downstream targets of PKC. Data are representative of
three independent experiments.
(B) HeLa cells transiently transfected with a PKC-specific FRET probe (CKAR)
and rat PKC bII-RFP were imaged to measure PKC activation in real time upon
stimulation with euphohelioscopin A or PMA. Base-line images were acquired
for 3 min before addition of euphohelioscopin A or PMA. The PKC inhibitor
Go¨6983 was added 35 min after the addition of euphohelioscopin A or PMA.
FRET ratios were measured by epifluorescence microscopy at 15 s intervals
and normalized to the baseline, the average FRET ratio measured before
compound addition. The normalized average FRET ratio is the average of
these corrected values ± SE.
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real-time fluorescence resonance energy transfer (FRET)-based
PKC activity assay using C kinase activity reporter (CKAR),
a reporter for PKC-mediated phosphorylation developed by
Violin et al. (2003). CKAR is a genetically encoded, fluorescent
PKC-specific substrate that undergoes a conformational change
when phosphorylated, which can be monitored by intramolecu-
lar FRET. Euphohelioscopin A (30 mM) was able to induce an
immediate, robust increase in PKC activity in HeLa cells cotrans-
fected with CKAR and rat PKC-bII-RFP; the observed activation
was reversed by the PKC inhibitor Go¨6983 (Figure 4B). Euphohe-
lioscopin A had no effect on CKAR T/A, a reporter lacking theChemistry & Biology 19, 994phosphoacceptor site. These results confirm that euphohelio-
scopin A acts as a PKC activator.
A comparison of the differentiation activities of euphohelio-
scopin A with known PKC activators revealed that phorbol
esters such as phorbol 12-myristate 13-acetate (PMA), phorbol
12,13-dibutyrate (PDBu), and mezerein afforded a very similar
phenotype in the CD34+ cell differentiation assay (Figure S2B)
as well as in their ability to differentiate and halt the prolifera-
tion of myeloid leukemia cell lines HL-60 (Figure S2C) and
THP-1 (Figure S3A). Importantly, PMA, a broad and ultrapotent
PKC activator, showed a very similar activity profile and re-
sponse to PKC inhibitors as euphohelioscopin A in all cell culture
assays (Figures 2A, 2B, S2, and S3A). Ingenol appeared 10-fold
less potent than euphohelioscopin A (Hasler et al., 1992), while
bryostatin 1 showed a very different activity profile (Kraft et al.,
1986); it showed a multiphasic dose-response curve in all dif-
ferentiation assays except the HL-60 differentiation assay,
where it failed to induce any increase in CD11b+ cells or any
decrease in total cell numbers comparable to euphohelioscopin
A. ADMB was not active in any of the cell culture assays. These
findings suggest that the properties of euphohelioscopin A
as a PKC activator may be more closely related to those of phor-
bol esters than to other families of natural and synthetic PKC
activators.
DISCUSSION
In summary, we have identified the natural product euphohe-
lioscopin A as a PKC activator and inducer of myeloid differen-
tiation. Due to its pivotal role in pathways governing cell pro-
liferation and differentiation, PKC has been a focus of interest
as a pharmacological target for cancer therapy for the last
3 decades. In particular, several PKC-activating compounds
have been investigated for their ability to induce differentiation
of malignant myeloid progenitors (Hampson et al., 2005; Han
et al., 1998b) or to alleviate chemotherapy-induced leukopenia
(Han et al., 1998a). Though phorbol esters were originally the
most promising candidates due to their potency, the need
to balance their benefits and their tumor-promoting effects
severely limited the scope of potential therapeutic applications.
This led to the development of alternative PKC activating natural
products such as bryostatins and ingenols, which differed in their
isozyme specificity, their kinetics of PKC activation and their
induction of PKC translocation to various subcellular compart-
ments (Clamp and Jayson, 2002; Hampson et al., 2005, 2010;
Kedei et al., 2004).
As more PKC ligands came to be known, it became clear
that, whether in vitro or in vivo, the spectrum of PKC-mediated
responses was very broad. This revived the interest in finding
molecules able to activate PKC with distinct activities and spec-
ificities. More recently, as structural details emerged on the
mechanism of PKC activation, several attempts to rationally
design PKC activating or inhibiting ligands have been described
(Baba et al., 2004; Boije af Gennas et al., 2009; Keck et al., 2010;
Kiriazis et al., 2011). In this report, we introduce another scaffold
to explore in this context: a lathyrane diterpene (Figure S1).
Although the full spectrum of activity of this novel class of activa-
tors on different PKC isozymes and leukemic cells remains to be
investigated, our results with euphohelioscopin A hint that this–1000, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 997
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Euphohelioscopin Anatural product could have properties distinguishing it from
currently known PKC activators.
PKC-dependent induction of myeloid differentiation is medi-
ated by PKC-a and -d but not PKC-bII (Mischak et al., 1993).
The observation that euphohelioscopin A is capable of induc-
ing differentiation suggests that the compound might activate
PKC-a and -d in addition to PKC-bII, and might therefore be
an activator of both conventional and novel PKCs. However,
the effects observed of euphohelioscopin A on CD34+ and mye-
loid leukemia cells are very different from the activity profiles that
have been reported for two potent activators of conventional and
novel PKCs: bryostatin 1 and ingenol-3-angelate (I3A). Bryosta-
tin 1 is not able to differentiate HL-60 cells (Figure S2; Kraft et al.,
1986) and shows a very different dose-response profile than eu-
phohelioscopin A in our HSC and THP1 differentiation assays
(Figure S2). These characteristics have been attributed to the
unique interaction between bryostatin 1 and PKC-d (Lorenzo
et al., 1997, 1999), a PKC linked to apoptosis in malignant cells.
While phorbol esters translocate this isoform to the plasma
membrane and cause its rapid downregulation, bryostatin 1
translocates it to the nuclear membrane (Wang et al., 1999),
and protects it from downregulation in a biphasic manner (Szal-
lasi et al., 1994). I3A is reported to have no antiproliferative
effects against CD34+ cells and to induce apoptosis rather
than differentiation in HL-60 cells (Hampson et al., 2005), unlike
the activity reported with PMA and unlike what we observed with
euphohelioscopin A. This particularity of I3A is also thought
to originate from its pattern of PKC-d translocation, primarily
to the nuclear and intracellular membranes (Hampson et al.,
2005; Kedei et al., 2004). In contrast, we found that phorbol
esters such as PMA closely recapitulated the phenotype of eu-
phohelioscopin A in the three cell types we tested. Since the
differences in activity between bryostatin 1, I3A and phorbol
esters are mediated by their differences in PKC-d activation
and subcellular translocation, this suggests that euphoheliosco-
pin A may behave similarly to phorbol esters in relation to this
isozyme.
Importantly, euphohelioscopin A also bears significant struc-
tural differences relative to PMA (Figure S1), including a less con-
strained structure than daphnane, ingenane, and tigliane diter-
penes (which comprise most known PKC-activating natural
products isolated from Euphorbiaceae). Second, euphohelio-
scopin A lacks several functional groups that are thought to be
important for the PKC binding and translocation induced by
phorbol esters, such as an ester in position 13, the hydroxyl
groups in positions 4, 9, and 20, and the carbonyl in position 3
(Blumberg, 1988; Nacro et al., 2000). Finally, the hydrophobic
side chain is shorter and unsaturated, a characteristic that has
been associated with modified intracellular distribution and
lower tumor promotion in phorbol esters (Fu¨rstenberger et al.,
1981; Wang et al., 1999, 2000). It will be interesting to determine
to what extent these differences in side chain hydrophobicity
and ring system strain each contribute to the kinetic differences
in PKC activation we observed between PMA and euphohelio-
scopin A: in addition to a 1,000-fold lower potency, the latter
showed a much slower rate of PKC activation (Figure 4B). This
is particularly significant since lower rates of activation have
been associated with differential phenotypic outcomes, includ-
ing decreased PKC inactivation and subsequent degradation,998 Chemistry & Biology 19, 994–1000, August 24, 2012 ª2012 Elseva more sustained signal, and lower tumor promotion (Hampson
et al., 2010).
These particularities highlight euphohelioscopin A and related
lathyrane diterpenes as a family of natural products worthy of
further investigation in the efforts toward safe and efficient phar-
macological induction of myeloid differentiation.
SIGNIFICANCE
Through an unbiased cell-based screen with primary human
CD34+ cells, we unveiled a biological activity of the plant
natural product euphohelioscopin A. Euphohelioscopin
A is able to induce myeloid differentiation in human hema-
topoietic stem and progenitor cells and in two myeloid
leukemia cell lines. These findings suggest a potential utility
of this scaffold for pharmacological intervention to alleviate
a shortage or dysregulation of myeloid cells in the clinical
setting. We were also able to determine the mechanism of
this bioactivity by showing that euphohelioscopin A is an
activator of protein kinase C; to our knowledge, this is the
first evidence of a lathyrane diterpene activating PKC, and
may shed new insights into theway ligands bind and activate
this family of proteins.
EXPERIMENTAL PROCEDURES
CD34+ Cell Culture
All experiments were performed in HSC expansion media (StemSpan SFEM,
StemCell Technologies) supplemented with 1 3 antibiotics and the following
recombinant human cytokines: thrombopoietin, IL-6, Flt3 ligand, and stem
cell factor (100 ng/ml, R&D Systems) unless otherwise indicated. Human
mPB CD34+ cells were purified from fresh human leukophoresed mobilized
peripheral blood (AllCells) using direct CD34 progenitor cell isolation kits (Mil-
tenyi Biotec) following manufacturer’s protocols. CD34+ cells were resus-
pended in HSC expansion medium (5 3 104 cells/ml) before being aliquoted
in 384-well plates (Greiner Bio-One). Compounds were added immediately
after plating. Cells were cultured at 37C in 5% CO2.
Flow Cytometry
Cells were stained in staining medium (HBSS supplemented with FBS [2%]
and EDTA [2 mM]) at 4C for 1 hr with PerCP anti-human CD34 (BD Biosci-
ence), PECy7 anti-CD45ra (eBiosciences), and PE anti-CD11b (BD Biosci-
ence), then washed with staining medium and analyzed. Multicolor analysis
for cell phenotyping was performed on a LSR II flow cytometer (Becton
Dickinson).
Colony Forming Assays
The progeny of 80 CD34+ cells after 7 days in culture were seeded in
serum-free methylcellulose containing SCF, IL-6, erythropoietin, IL-3, granu-
locyte and granulocyte-macrophage colony stimulating factor (MethoCult
SFH4436, StemCell Technologies), supplemented with 13 antibiotics, throm-
bopoietin, and Flt3 ligand. Colonies were scored on day 14 with an inverted
microscope at 403 magnification. Numbers reported represent the average
of the number of colonies scored from three dishes.
Western Blots
HEK293T cells (2 3 106) were serum starved overnight, then treated with eu-
phohelioscopin A, PMA or vehicle. After 10 min of compound treatment, cells
were washed with cold PBS, then lysed with 100 ml of RIPA buffer supple-
mented with a protease inhibitor cocktail (Sigma). Following incubation on
ice for 20 min, the lysed cells were passed through a 261/2 syringe needle
and centrifuged (15,000 3 g, 20 min at 4C). Cell lysates were denatured by
boiling in SDS sample buffer (Invitrogen) containing 5% b-mercaptoethanol.
Proteins were electrophoresed, transferred onto a polyvinylidene fluorideier Ltd All rights reserved
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MARCKS, and antiphospho-MARCKS (all from Cell Signaling Technology),
as well as antitubulin (Sigma) antibodies at suggested concentrations in Tris-
buffered saline containing 0.1% Tween 20 and 5% nonfat dry milk. Blots
were then incubated with HRP conjugated secondary antibodies and detected
with a chemiluminescent substrate (Thermo Scientific).
Materials
Phorbol 12-myristate 13-acetate (PMA) and Go¨ 6983 were purchased from
Calbiochem. Euphohelioscopin A was obtained from the Shanghai Institute
of Materia Medica, Shanghai, China.
Cell Culture
HEK293T and HeLa cells were maintained in Dulbecco’s modified Eagle’s
medium (Cellgro) containing 10% fetal bovine serum (GIBCO), at 37C, in
5% CO2. THP-1 and HL-60 cells were maintained in RPMI1640 (Cellgro) con-
taining 10% fetal bovine serum, at 37C, in 5% CO2.
Plasmid Constructs
The construction of CKAR and of C-terminally tagged rat PKC bII-RFP has
been previously described (Gould et al., 2009; Violin et al., 2003).
Cell Transfection
Cells were plated onto Lab-Tek chambered #1.0 borosilicate cover glass
(Nunc) prior to transfection. Transient transfection of CKAR and rat PKC
bII-RFP DNA was carried out using jetPRIME (Polyplus transfection). Cells
were imaged approximately 24 hr following transfection.
FRET Imaging and Analysis
HeLa cells were rinsed with and imaged at room temperature in Hanks’
balanced salt solution (Cellgro) supplemented with 1 mM CaCl2. CFP, YFP,
FRET, and RFP images were acquired and analyzed as described previously
(Gallegos et al., 2006). RFP emission wasmonitored during the imaging exper-
iments as a control for PKC expression levels. Baseline images were acquired
for 3 or more minutes before ligand addition. PKC inhibitor Go¨6983 was added
35 min after ligand addition. Individual data traces were normalized to 1 by
dividing by the average base-line FRET ratio, and data from at least three
different imaging dishes were referenced around the ligand addition time
point. The normalized average FRET ratio is the average of these corrected
values ± SE.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and can be found with this
article online at http://dx.doi.org/10.1016/j.chembiol.2012.06.010.
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